Nevolat Daily Weight Loss Injection

Name: Nevolat Daily Weight Loss Injection - UK Registered Online Pharmacy
Availability: InStock

Price range: £124.99 through £213.09

Nevolat is a daily, self-administered weight loss injection containing Liraglutide, a GLP-1 receptor agonist. It mimics the body’s natural hormone to regulate appetite and blood sugar levels, helping you feel fuller for longer and reducing hunger cravings.

Available Strength

Available Quantity

Clear

SKU: N/A Category: Weight Management Tags: Nevolat, Nevolat Daily Weight Loss Injection, Weight Loss Injection

Nevolat is a once-daily, self-administered weight loss injection containing liraglutide, a GLP-1 receptor agonist. It mimics the action of the natural hormone GLP-1, which regulates appetite and food intake. By slowing gastric emptying and increasing feelings of fullness, Nevolat helps reduce calorie consumption, supporting weight loss when combined with a reduced-calorie diet and increased physical activity.

Who can use Nevolat?

Adults (18 years and older)

Nevolat is suitable for adults who meet the following conditions:

BMI of 30 kg/m² or higher: Classified as obese.

BMI between 27 kg/m² and 29.9 kg/m²: Classified as overweight, accompanied by at least one weight-related health condition, such as:

Type 2 diabetes or pre-diabetes
High blood pressure (hypertension)
High cholesterol (dyslipidaemia)
Obstructive sleep apnoea

Warnings

Do not use Nevolat if you are allergic to liraglutide or any of its ingredients.
Nevolat is not recommended for individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Consult your doctor if you have pancreatitis, severe gastrointestinal disease, or liver or kidney problems.
Nevolat is not a substitute for insulin and should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.
Pregnancy and breastfeeding: Nevolat is not recommended during pregnancy or while breastfeeding.
Always consult your healthcare provider before starting Nevolat to ensure it’s appropriate for you.

Directions

Starting Dose: Begin with 0.6 mg once daily for one week.

Titration: Increase the dose by 0.6 mg each week until reaching the maintenance dose of 3.0 mg daily.

Week 1: 0.6 mg

Week 2: 1.2 mg

Week 3: 1.8 mg

Week 4: 2.4 mg

Week 5 onwards: 3.0 mg

Administration: Inject subcutaneously into the abdomen, thigh, or upper arm. Rotate injection sites to prevent irritation.

Timing: Administer at the same time each day, with or without food.

If you experience side effects, consult with our clinicians before increasing the dose.

Ingredients

Active Ingredient

Liraglutide — Each 1 mL of solution contains 6 mg of liraglutide, and each 3 mL pre-filled pen holds a total of 18 mg

Inactive Ingredients (Excipients)

Per 1 mL of solution, Nevolat contains:

Disodium phosphate dihydrate – 1.42 mg
Propylene glycol – 14 mg
Phenol – 5.5 mg
Water for injection, q.s. (to make up to 1 mL of solution)

Side Effects

Like all medicines, Nevolat can cause side effects, although not everyone will experience them. Most side effects are mild to moderate and improve as your body adjusts to treatment.

Very Common Side Effects (may affect more than 1 in 10 people)

Nausea (feeling sick)
Vomiting
Diarrhoea
Constipation
Headache

Common Side Effects (may affect up to 1 in 10 people)

Indigestion, bloating, or stomach discomfort
Dizziness
Tiredness or low energy
Loss of appetite
Injection site reactions (redness, swelling, or bruising)
Low blood sugar (particularly if used with insulin or sulfonylureas)
Gallstones

Uncommon Side Effects (may affect up to 1 in 100 people)

Increased heart rate
Mild allergic reactions such as rash or itching
Dehydration (from vomiting or diarrhoea)

Rare but Serious Side Effects

⚠️ Stop treatment and seek urgent medical attention if you experience:

Pancreatitis: severe, persistent stomach pain (sometimes spreading to the back), often with nausea/vomiting
Severe allergic reaction (anaphylaxis): swelling of face, lips, tongue or throat, difficulty breathing
Gallbladder problems: sudden stomach pain, fever, yellowing of the skin or eyes (jaundice)

Long-Term Risks Under Review

Pre-clinical studies in animals showed thyroid tumours with liraglutide. Although the relevance to humans is unclear, Nevolat should not be used in patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).

Important Notes

Nausea is the most common side effect at the start of treatment and usually settles after a few days to weeks.
Drink plenty of fluids to avoid dehydration if experiencing vomiting or diarrhoea.
Report any side effects to your prescriber or through the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk).